Published in

Bentham Science Publishers, Current Cancer Drug Targets, 5(15), p. 435-444

DOI: 10.2174/1568009615666150407124747

Links

Tools

Export citation

Search in Google Scholar

Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)

Journal article published in 2015 by Angela Lamarca ORCID, Marta Mendiola, Elsa Bernal, Victoria Heredia, Esther Díaz, María Miguel, Laura Pastrian, Emilio Burgos, Jaime Feliu, Jorge Barriuso
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Hepatocellular carcinoma (HCC) tends to develop in the liver when there is a high level of background inflammation (cirrhosis). Treatment options are limited and mainly based on systemic therapies such as anti-angiogenic drugs (e.g. sorafenib). Connective tissue growth factor (CTGF) is a matricellular protein involved in inflammation, tumour growth and angiogenesis. The aim of this study is to determine the expression of CTGF and hypoxia inducible factors (HIF) in HCC and to clarify its impact on relapse and survival.